Hamajima N, Tajima K, Tominaga S, Matsuura A, Kuwabara M, Okuma K
Division of Epidemiology, Aichi Cancer Center Hospital.
Jpn J Cancer Res. 1999 Feb;90(2):136-43. doi: 10.1111/j.1349-7006.1999.tb00726.x.
Following a phase I study, a phase II study was conducted to evaluate the effects of two different doses of tea polyphenols on serum pepsinogen levels. Subjects were patients aged 40 to 69 years who had undergone gastroscopy between 1995 and 1997 at Aichi Cancer Center Hospital, and had been found to have no disease requiring medication. Those with pepsinogen I < 70 ng/ml and pepsinogen I/II ratio < 6 were included in this study. Capsules containing 100 mg of tea polyphenols were administered for 1 year: 1 capsule per day for 101 patients (42 males and 59 females), and 6 capsules (equivalent to 10 cups) per day for 83 patients (30 males and 53 females). The enrollment of the 1 capsule group preceded that of the 6 capsule group, in which re-participation was allowed. Blood samples were obtained 1 year after participation from 86 participants of the 1 capsule group and 77 participants (43 new participants and 34 re-participants) of the 6 capsule group. The compliance in polyphenol capsule intake ranged from 11.4 to 105.7% (87.6% on average) of the scheduled amount for the 1 capsule group and 3.2 to 112.3% (77.8% on average) for the 6 capsule group. No serious polyphenol-related adverse effects were reported. The difference in pepsinogen I between before and after 1 year intake of the polyphenol was 3.1 ng/ml for the 43 participants of the 6 capsule group, but 3.5 ng/ml for the 1 capsule group. The mean pepsinogen I/II ratio for the 43 participants increased from 2.37 by 0.08. This increase was not larger than that for the 1 capsule group (from 2.61 by 0.11). Among 34 participants in both interventions, no significant increase in pepsinogen I and I/II ratio for the 6 capsule intervention was observed. This result suggests that additional polyphenol intake for 1 year in Japanese does not improve pepsinogen levels, which are considered to reflect stomach atrophy, a high-risk condition for stomach cancer.
在一项I期研究之后,进行了一项II期研究,以评估两种不同剂量的茶多酚对血清胃蛋白酶原水平的影响。研究对象为1995年至1997年期间在爱知癌症中心医院接受胃镜检查且未发现需要药物治疗疾病的40至69岁患者。胃蛋白酶原I<70 ng/ml且胃蛋白酶原I/II比值<6的患者被纳入本研究。含100 mg茶多酚的胶囊服用1年:101例患者(42例男性和59例女性)每天服用1粒胶囊,83例患者(30例男性和53例女性)每天服用6粒胶囊(相当于10杯)。1粒胶囊组的入组先于6粒胶囊组,6粒胶囊组允许再次参与。参与1年后,从1粒胶囊组的86名参与者和6粒胶囊组的77名参与者(43名新参与者和34名再次参与者)中采集血样。1粒胶囊组茶多酚胶囊摄入量的依从性为计划量的11.4%至105.7%(平均87.6%),6粒胶囊组为3.2%至112.3%(平均77.8%)。未报告与茶多酚相关的严重不良反应。6粒胶囊组的43名参与者在摄入茶多酚1年前后胃蛋白酶原I的差异为3.1 ng/ml,而1粒胶囊组为3.5 ng/ml。43名参与者的胃蛋白酶原I/II平均比值从2.37增加了0.08。这一增加幅度不大于1粒胶囊组(从2.61增加了0.11)。在两种干预措施的34名参与者中,未观察到6粒胶囊干预使胃蛋白酶原I和I/II比值有显著增加。该结果表明,日本人额外摄入1年茶多酚并不能改善胃蛋白酶原水平,胃蛋白酶原水平被认为反映了胃萎缩,而胃萎缩是胃癌的高危状况。